Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration

Brit Mollenhauer, Valerie Cullen, Ilana Kahn, Bryan Krastins, Tiago F. Outeiro, Imelda Pepivani, Juliana Ng, Walter Schulz-Schaeffer, Hans A. Kretzschmar, Pamela J. McLean, Claudia Trenkwalder, David A. Sarracino, Jean Paul VonSattel, Joseph J. Locascio, Omar Ali El-Agnaf, Michael G. Schlossmacher

Research output: Contribution to journalArticle

264 Citations (Scopus)

Abstract

Because accumulation of α-synuclein (αS) in the brain is a hallmark of Parkinson disease (PD) and related disorders, we examined its occurrence in human cerebrospinal fluid (CSF). Following affinity enrichment and trypsin digestion of CSF collected from a neurologically healthy donor, we identified several αS-derived peptides by mass spectrometry. The concentration of αS amounted to < 0.001% of the CSF proteome. We then built, validated and optimized a sandwich-type, enzyme-linked immunoadsorbent assay (ELISA) to measure total αS levels in unconcentrated CSF. In a cross-sectional study of 100 living donors, we examined cell-free CSF samples from subjects clinically diagnosed with advanced PD, dementia with Lewy bodies (DLB), Alzheimer disease (AD), and a group of non-neurodegenerative disease controls (NCO). In these four groups the CSF αS concentrations ranged from 0.8 to 16.2 pg/μl. Mean CSF αS values were lower in donors with a primary synucleinopathy (PD, DLB: n = 57) than in the other two groups (AD, NCO: n = 35; p = 0.025). By contrast, living Creutzfeldt-Jakob disease patients showed markedly elevated CSF αS levels (n = 8; mean, 300 pg/μl; p < 0.001). Our results unequivocally confirm the presence of αS in adult human CSF. In a first feasibility study employing a novel ELISA, we found relatively low CSF αS concentrations in subjects with parkinsonism linked to synucleinopathy, PD and DLB. In definite prion disease cases, we recorded a marked rise in total CSF αS resulting from rapid cell death. Our results will likely aid future biomarker explorations in neurodegenerative conditions and facilitate target validation studies.

Original languageEnglish
Pages (from-to)315-325
Number of pages11
JournalExperimental Neurology
Volume213
Issue number2
DOIs
Publication statusPublished - Oct 2008
Externally publishedYes

Fingerprint

Synucleins
Immunosorbents
Cerebrospinal Fluid
Cross-Sectional Studies
Enzymes
Lewy Body Disease
Parkinson Disease
Alzheimer Disease
Tissue Donors
Creutzfeldt-Jakob Syndrome
Prion Diseases
Validation Studies
Living Donors
Parkinsonian Disorders
Feasibility Studies
Proteome
Neurodegenerative Diseases
Trypsin
Dementia
Digestion

Keywords

  • α-synuclein
  • Biomarker
  • Cerebrospinal fluid
  • Dementia
  • ELISA
  • Mass spectrometry
  • Parkinsonism

ASJC Scopus subject areas

  • Neurology
  • Neuroscience(all)

Cite this

Mollenhauer, B., Cullen, V., Kahn, I., Krastins, B., Outeiro, T. F., Pepivani, I., ... Schlossmacher, M. G. (2008). Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. Experimental Neurology, 213(2), 315-325. https://doi.org/10.1016/j.expneurol.2008.06.004

Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. / Mollenhauer, Brit; Cullen, Valerie; Kahn, Ilana; Krastins, Bryan; Outeiro, Tiago F.; Pepivani, Imelda; Ng, Juliana; Schulz-Schaeffer, Walter; Kretzschmar, Hans A.; McLean, Pamela J.; Trenkwalder, Claudia; Sarracino, David A.; VonSattel, Jean Paul; Locascio, Joseph J.; Ali El-Agnaf, Omar; Schlossmacher, Michael G.

In: Experimental Neurology, Vol. 213, No. 2, 10.2008, p. 315-325.

Research output: Contribution to journalArticle

Mollenhauer, B, Cullen, V, Kahn, I, Krastins, B, Outeiro, TF, Pepivani, I, Ng, J, Schulz-Schaeffer, W, Kretzschmar, HA, McLean, PJ, Trenkwalder, C, Sarracino, DA, VonSattel, JP, Locascio, JJ, Ali El-Agnaf, O & Schlossmacher, MG 2008, 'Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration', Experimental Neurology, vol. 213, no. 2, pp. 315-325. https://doi.org/10.1016/j.expneurol.2008.06.004
Mollenhauer, Brit ; Cullen, Valerie ; Kahn, Ilana ; Krastins, Bryan ; Outeiro, Tiago F. ; Pepivani, Imelda ; Ng, Juliana ; Schulz-Schaeffer, Walter ; Kretzschmar, Hans A. ; McLean, Pamela J. ; Trenkwalder, Claudia ; Sarracino, David A. ; VonSattel, Jean Paul ; Locascio, Joseph J. ; Ali El-Agnaf, Omar ; Schlossmacher, Michael G. / Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration. In: Experimental Neurology. 2008 ; Vol. 213, No. 2. pp. 315-325.
@article{fac804b27e364b50a27682c033310ba3,
title = "Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration",
abstract = "Because accumulation of α-synuclein (αS) in the brain is a hallmark of Parkinson disease (PD) and related disorders, we examined its occurrence in human cerebrospinal fluid (CSF). Following affinity enrichment and trypsin digestion of CSF collected from a neurologically healthy donor, we identified several αS-derived peptides by mass spectrometry. The concentration of αS amounted to < 0.001{\%} of the CSF proteome. We then built, validated and optimized a sandwich-type, enzyme-linked immunoadsorbent assay (ELISA) to measure total αS levels in unconcentrated CSF. In a cross-sectional study of 100 living donors, we examined cell-free CSF samples from subjects clinically diagnosed with advanced PD, dementia with Lewy bodies (DLB), Alzheimer disease (AD), and a group of non-neurodegenerative disease controls (NCO). In these four groups the CSF αS concentrations ranged from 0.8 to 16.2 pg/μl. Mean CSF αS values were lower in donors with a primary synucleinopathy (PD, DLB: n = 57) than in the other two groups (AD, NCO: n = 35; p = 0.025). By contrast, living Creutzfeldt-Jakob disease patients showed markedly elevated CSF αS levels (n = 8; mean, 300 pg/μl; p < 0.001). Our results unequivocally confirm the presence of αS in adult human CSF. In a first feasibility study employing a novel ELISA, we found relatively low CSF αS concentrations in subjects with parkinsonism linked to synucleinopathy, PD and DLB. In definite prion disease cases, we recorded a marked rise in total CSF αS resulting from rapid cell death. Our results will likely aid future biomarker explorations in neurodegenerative conditions and facilitate target validation studies.",
keywords = "α-synuclein, Biomarker, Cerebrospinal fluid, Dementia, ELISA, Mass spectrometry, Parkinsonism",
author = "Brit Mollenhauer and Valerie Cullen and Ilana Kahn and Bryan Krastins and Outeiro, {Tiago F.} and Imelda Pepivani and Juliana Ng and Walter Schulz-Schaeffer and Kretzschmar, {Hans A.} and McLean, {Pamela J.} and Claudia Trenkwalder and Sarracino, {David A.} and VonSattel, {Jean Paul} and Locascio, {Joseph J.} and {Ali El-Agnaf}, Omar and Schlossmacher, {Michael G.}",
year = "2008",
month = "10",
doi = "10.1016/j.expneurol.2008.06.004",
language = "English",
volume = "213",
pages = "315--325",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration

AU - Mollenhauer, Brit

AU - Cullen, Valerie

AU - Kahn, Ilana

AU - Krastins, Bryan

AU - Outeiro, Tiago F.

AU - Pepivani, Imelda

AU - Ng, Juliana

AU - Schulz-Schaeffer, Walter

AU - Kretzschmar, Hans A.

AU - McLean, Pamela J.

AU - Trenkwalder, Claudia

AU - Sarracino, David A.

AU - VonSattel, Jean Paul

AU - Locascio, Joseph J.

AU - Ali El-Agnaf, Omar

AU - Schlossmacher, Michael G.

PY - 2008/10

Y1 - 2008/10

N2 - Because accumulation of α-synuclein (αS) in the brain is a hallmark of Parkinson disease (PD) and related disorders, we examined its occurrence in human cerebrospinal fluid (CSF). Following affinity enrichment and trypsin digestion of CSF collected from a neurologically healthy donor, we identified several αS-derived peptides by mass spectrometry. The concentration of αS amounted to < 0.001% of the CSF proteome. We then built, validated and optimized a sandwich-type, enzyme-linked immunoadsorbent assay (ELISA) to measure total αS levels in unconcentrated CSF. In a cross-sectional study of 100 living donors, we examined cell-free CSF samples from subjects clinically diagnosed with advanced PD, dementia with Lewy bodies (DLB), Alzheimer disease (AD), and a group of non-neurodegenerative disease controls (NCO). In these four groups the CSF αS concentrations ranged from 0.8 to 16.2 pg/μl. Mean CSF αS values were lower in donors with a primary synucleinopathy (PD, DLB: n = 57) than in the other two groups (AD, NCO: n = 35; p = 0.025). By contrast, living Creutzfeldt-Jakob disease patients showed markedly elevated CSF αS levels (n = 8; mean, 300 pg/μl; p < 0.001). Our results unequivocally confirm the presence of αS in adult human CSF. In a first feasibility study employing a novel ELISA, we found relatively low CSF αS concentrations in subjects with parkinsonism linked to synucleinopathy, PD and DLB. In definite prion disease cases, we recorded a marked rise in total CSF αS resulting from rapid cell death. Our results will likely aid future biomarker explorations in neurodegenerative conditions and facilitate target validation studies.

AB - Because accumulation of α-synuclein (αS) in the brain is a hallmark of Parkinson disease (PD) and related disorders, we examined its occurrence in human cerebrospinal fluid (CSF). Following affinity enrichment and trypsin digestion of CSF collected from a neurologically healthy donor, we identified several αS-derived peptides by mass spectrometry. The concentration of αS amounted to < 0.001% of the CSF proteome. We then built, validated and optimized a sandwich-type, enzyme-linked immunoadsorbent assay (ELISA) to measure total αS levels in unconcentrated CSF. In a cross-sectional study of 100 living donors, we examined cell-free CSF samples from subjects clinically diagnosed with advanced PD, dementia with Lewy bodies (DLB), Alzheimer disease (AD), and a group of non-neurodegenerative disease controls (NCO). In these four groups the CSF αS concentrations ranged from 0.8 to 16.2 pg/μl. Mean CSF αS values were lower in donors with a primary synucleinopathy (PD, DLB: n = 57) than in the other two groups (AD, NCO: n = 35; p = 0.025). By contrast, living Creutzfeldt-Jakob disease patients showed markedly elevated CSF αS levels (n = 8; mean, 300 pg/μl; p < 0.001). Our results unequivocally confirm the presence of αS in adult human CSF. In a first feasibility study employing a novel ELISA, we found relatively low CSF αS concentrations in subjects with parkinsonism linked to synucleinopathy, PD and DLB. In definite prion disease cases, we recorded a marked rise in total CSF αS resulting from rapid cell death. Our results will likely aid future biomarker explorations in neurodegenerative conditions and facilitate target validation studies.

KW - α-synuclein

KW - Biomarker

KW - Cerebrospinal fluid

KW - Dementia

KW - ELISA

KW - Mass spectrometry

KW - Parkinsonism

UR - http://www.scopus.com/inward/record.url?scp=49449105990&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=49449105990&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2008.06.004

DO - 10.1016/j.expneurol.2008.06.004

M3 - Article

C2 - 18625222

AN - SCOPUS:49449105990

VL - 213

SP - 315

EP - 325

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

IS - 2

ER -